Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study-Reference-Cited by-同舟云学术

Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study

Published:2017-04-25 Issue:7 Volume:33 Page:1223-1230
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Li Changgang¹,Zhang Xinsheng²,Zhao Yongqiang³,Wu Runhui⁴,Hu Qun⁵,Xu Weiqun⁶,Sun Jing⁷,Yang Renchi⁸,Li Xiaojing⁹,Zhou Rongfu¹⁰,Lian Shinmei¹¹,Gu Jian¹²,Wu Junde¹³,Hou Qingsong¹³

Affiliation:

1. Department of Hematology and Oncology, Shenzhen Children’s Hospital, Shenzhen, China;

2. Hemophilia Treatment Centre, Shandong Blood Centre, China;

3. Department of Hematology, Peking Union Medical College Hospital, Beijing, China;

4. Hematology/Oncology Centre, Beijing Children’s Hospital, Capital Medical University, Beijing, China;

5. Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (HUST), Hankou, Wuhan, China;

6. Department of Hematology, The Children’s Hospital, Zhengjiang University School of Medicine, Hangzhou, China;

7. Department of Hematology, Nan fang Hospital, Southern Medical University, Guangzhou, China;

8. Thrombosis and Hemostasis Centre, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;

9. Department of Hematology, Chengdu Women & Children’s Central Hospital, Chengdu, China;

10. Department of Hematology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China;

11. Department of Hematology, Dalian Municipal Central Hospital, Dalian Medical University, Dalian, China;

12. Department of Hematology, Northern Jiangsu People’s Hospital, Clinical Medical School of Yangzhou University, Yangzhou;

13. Bayer HealthCare Pharmaceuticals Inc., Bayer Centre, Beijing, China

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1310720

Reference44 articles.

1. Fast Facts About Bleeding Disorders. National Hemophilia Foundation. Available at: https://www.hemophilia.org/About-Us/Fast-Facts [Last accessed 1 January 2016]

2. Hemophilia A. National Organization for Rare Disorders. Available at: https://rarediseases.org/rare-diseases/hemophilia-a/ [Last accessed 1 January 2016]

3. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens

4. MASAC Recommendation Concerning Prophylaxis. National Hemophilia Foundation. Available at: https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis [Last accessed 1 January 2016]

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study;European Journal of Haematology;2024-07-19

2. Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe hemophilia A in China: using real-world data;Orphanet Journal of Rare Diseases;2023-08-04

3. Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe haemophilia A in China: using real-world data;2023-04-20

4. The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033;Haemophilia;2022-06-17

5. Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review;Orphanet Journal of Rare Diseases;2021-06-26